English
This article is from Journal of Advanced Pharmaceutical Technology & Research , volume 5 . Abstract The objective of this study was to develop a novel implant containing risperidone intended for long-term treatment in Schizophrenia utilizing in vitro in vivo correlation (IVIVC) studies. Different implants (F1-F8) containing an antipsychotic drug, risperidone, were prepared using a hot melt extrusion technique by taking polycaprolactones of different molecular weights (Mwt. 15000, 45000, 80000) either alone or as their blends, and PLGA (75:25). The implants contained 40% of the drug. After fabrication, the implants were characterized for various in vitro properties such as drug release and physical strength. Prior to conducting drug release studies, optimum drug release method was developed based on IVIVC studies. An optimized formulation based on drug release and physical strength at the end of fabrication was selected from the various implants fabricated. The bioactivity, reversibility, and IVIVC of optimized formulation were determined using pharmacokinetic studies in rats. Short-term stability studies were conducted with optimized formulation. Drug release depended on polymer mo
Sign in with your free account to read, download EPUBs or listen.
Ebook · Development of novel risperidone implants using blends of polycaprolactones and in vitro in vivo correlation studies. · Navitha, Aerrolla, Jogala, Satheesh, Krishnamohan, Chinnala, Aukunuru, Jithan · Internet Archive